Table 8.
Evidence of BTK inhibitors in patients with MZL
| Patients type | BTK inhibitor regimens | Efficacy | Study | Phase | N |
|---|---|---|---|---|---|
| Patients with R/R MZL | Zanubrutinib | ORR: 68.2%; CR rate: 25.8%; median PFS: NR | MAGNOLIA [126] | 2 | 68 |
| Acalabrutinib | ORR: 53%; CR rate: 13%; median PFS: 27.4 months | ACE-LY-003 [127] | 1/2 | 43 | |
| Ibrutinib | ORR: 58%; CR rate: 10%; median PFS: 15.7 months | PCYC-1121 [128] | 2 | 63 |
BTK, Bruton tyrosine kinase; CR, complete response; R/R, relapsed/refractory; MZL, marginal zone B-cell lymphoma; NR, not reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; R/R, relapsed/refractory